- Home
- RYM vs KLRS Comparison
RYM vs KLRS Comparison
Compare RYM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYM | KLRS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 46.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RYM | KLRS |
|---|---|---|
| Price | $16.24 | $8.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 23.3K | ★ 49.4K |
| Earning Date | 03-20-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,303,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1338.92 | N/A |
| 52 Week Low | $13.22 | $2.14 |
| 52 Week High | $53.65 | $12.90 |
Technical Indicators
Market Signals| Indicator | RYM | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 46.22 |
| Support Level | $14.73 | $8.25 |
| Resistance Level | $18.75 | $10.28 |
| Average True Range (ATR) | 1.92 | 0.80 |
| MACD | 0.16 | -0.07 |
| Stochastic Oscillator | 31.73 | 17.99 |
Price Performance
Historical ComparisonAbout RYM RYTHM Inc.
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.